SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI
Por:
Metra, M, Tomasoni, D, Adamo, M, Amir, O, Anker, SD, Bayes-Genis, A, Boehm, M, Butler, J, Chioncel, O, Filippatos, G, Gustafsson, F, Jankowska, EA, Kaski, JC, Moura, B, Petrie, MC, Ponikowski, P, Rakisheva, A, Ristic, A, Roubille, F, Savarese, G, Seferovic, P, van der Meer, P, Volterrani, M, Coats, AJ, Chopra, VK and Rosano, G
Publicada:
1 dic 2025
Ahead of Print:
1 sep 2025
Resumen:
In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium-glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF). Further trials showed efficacy of empagliflozin and dapagliflozin in patients with HF with preserved ejection fraction (HFpEF). These results prompted a broadened recommendation for the SGLT2 inhibitors dapagliflozin or empagliflozin across the whole left ventricular ejection fraction (LVEF) spectrum in the 2023 Focused Update of the ESC HF guidelines and in other international guidelines. In SOLOIST-WHF and EMPULSE, sotagliflozin (enrolling only patients with T2DM) and empagliflozin, respectively, were beneficial when initiated at the end or soon after an episode of decompensated HF. Based on these results and on the early appearance of their beneficial effects, the administration of SGLT2 inhibitors should start early in patients hospitalized for acute HF. Analyses after study drug withdrawal in randomized clinical trials have shown that their benefits may decline rapidly after discontinuation, and thus, persistence of treatment is advised. In EMPACT-MI, empagliflozin did not reduce the primary outcome of cardiovascular (CV) death/HF hospitalization but reduced first/recurrent HF hospitalizations. Potential benefits of SGLT2 inhibitors in further specific conditions (i.e., cardiac amyloidosis, grown-up congenital heart disease and paediatric patients with HF) have been reported in observational studies but need confirmation from prospective trials. This scientific statement summarizes current evidence regarding the effects of SGLT2 inhibitors for the prevention and treatment of HF.
Filiaciones:
Metra, M:
Univ Brescia, ASST Spedali Civili Brescia, Cardiol, Brescia, Italy
Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Brescia, Italy
Tomasoni, D:
Univ Brescia, ASST Spedali Civili Brescia, Cardiol, Brescia, Italy
Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Brescia, Italy
Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden
Adamo, M:
Univ Brescia, ASST Spedali Civili Brescia, Cardiol, Brescia, Italy
Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Brescia, Italy
Amir, O:
Hebrew Univ Jerusalem, Fac Med, Hadassah Med Ctr, Dept Cardiol, Jerusalem, Israel
Anker, SD:
Charite Univ Med Berlin, Dept Cardiol CVK, German Ctr Cardiovasc Res DZHK, German Heart Ctr Charite,Partner Site Berlin, Berlin, Germany
:
Hosp Badalona Germans Trias & Pujol, Heart Inst, CIBERCV, Badalona, Barcelona, Spain
Boehm, M:
Saarland Univ, Klin Innere Med 3, Univ Klinikum Saarlandes, Homburg, Germany
Butler, J:
Baylor Scott & White Res Inst, Dallas, TX USA
Univ Mississippi, Jackson, MS USA
Chioncel, O:
Univ Med & Pharm Carol Davila, Emergency Inst Cardiovasc Dis Prof CC Iliescu, Bucharest, Romania
Filippatos, G:
Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
Gustafsson, F:
Univ Copenhagen, Heart Ctr, Dept Cardiol, Rigshosp, Copenhagen, Denmark
Jankowska, EA:
Wroclaw Med Univ, Inst Heart Dis, Wroclaw, Poland
Kaski, JC:
St Georges Univ London, Mol & Clin Sci Res Inst, London, England
Moura, B:
Ctr Invest Tecnol & Serv Saude, Porto, Portugal
Hosp Forcas Armadas Polo Porto, Serv Cardiol, Porto, Portugal
Petrie, MC:
Univ Glasgow, Sch Cardiovasc & Metab Hlth, Glasgow City, England
Ponikowski, P:
Wroclaw Med Univ, Inst Heart Dis, Wroclaw, Poland
Wroclaw Med Univ, Dept Cardiol, Wroclaw, Poland
Rakisheva, A:
Sci Inst Cardiol & Internal Dis, Dept Cardiol, Alma Ata, Kazakhstan
Ristic, A:
Univ Belgrade, Sch Med, Belgrade, Serbia
Roubille, F:
Univ Montpellier, Cardiol Dept, CHU Montpellier, PhyMedExp,INSERM,CNRS, Montpellier, France
Savarese, G:
Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden
Seferovic, P:
Serbian Acad Arts & Sci, Belgrade, Serbia
van der Meer, P:
Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands
Volterrani, M:
IRCCS San Raffaele Pisana, Ctr Clin & Basic Res, Dept Med Sci, Rome, Italy
Coats, AJ:
Heart Res Inst, Newtown, NSW, Australia
Chopra, VK:
Medanta, Dept Cardiol, Gurgaon, Haryana, India
Rosano, G:
San Raffaele Open Univ Rome, Dept Human Sci & Promot Qual Life, Rome, Italy
IRCCS San Raffaele, Rome, Italy
Green Accepted, Green Submitted, gold
|